Creon 180000 [USP'U]/1

Creon 180000 [USP'U]/1 is a pancreatic enzyme replacement therapy designed to aid digestion in individuals with exocrine pancreatic insufficiency. This delayed-release capsule contains pancrelipase, helping to break down fats, proteins, and carbohydrates. Ideal for those needing digestive support, Creon is manufactured by AbbVie Inc. in the USA.

Creon 180000 [USP'U]/1 is primarily used to manage exocrine pancreatic insufficiency, a condition where the pancreas does not produce enough digestive enzymes. This medication helps the body digest fats, proteins, and carbohydrates more effectively. It is often prescribed for individuals with chronic pancreatitis, cystic fibrosis, or other conditions affecting pancreatic function. Creon is taken orally and works by releasing enzymes in the small intestine to aid digestion.

Common effects of Creon 180000 [USP'U]/1 may include improved digestion and nutrient absorption. Some users might experience mild gastrointestinal discomfort, such as bloating or gas, as the body adjusts to the enzyme supplementation. It is important to follow the prescribed dosage and administration instructions to minimize potential side effects.

Creon 180000 [USP'U]/1 should be stored at room temperature and kept out of reach of children. It is essential to swallow the capsules whole and not crush or chew them to ensure the delayed-release mechanism works effectively. Individuals with known allergies to pork proteins should consult their healthcare provider before using this medication.

Creon 180000 [USP'U]/1 may interact with certain medications, particularly those affecting gastrointestinal pH or motility. It is advisable to inform your healthcare provider about all medications you are taking to avoid potential interactions. Additionally, high-fiber diets or certain antacids might impact the effectiveness of Creon.